Spots Global Cancer Trial Database for Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
Official Title: Conventional Postoperative Radiotherapy (Standard Fractionation) Plus Iressa or Hyperfractionated Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer: A Phase I Pilot Trial
Study ID: NCT00681967
Conditions
Study Description
Brief Summary: To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Basel, , Switzerland
Research Site, Bern, , Switzerland
Contact Details
Name: Christoph Rochlitz, Prof Dr med
Affiliation: University Hospital of Basel
Role: PRINCIPAL_INVESTIGATOR
Name: Madeleine Billeter, MD
Affiliation: AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland
Role: STUDY_DIRECTOR
Name: Verena Renggli
Affiliation: AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
